16 publications
Name | Date | Type | Actions |
---|---|---|---|
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
26/10/2023 | Public releases | |
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
18/01/2023 | Public releases | |
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
20/04/2023 | Public releases | |
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
20/07/2022 | Public releases | |
Q1 2022 SALES: €135M Q1 2022 SALES: €135M |
13/04/2022 | Public releases | |
First nine months 2022 sales: €405M In line with year-end outlook |
12/10/2022 | Public releases | |
Continued Sales Growth in the second Quarter of 2010 Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth. |
16/07/2010 | Public releases | |
Continued sales growth driven by sustained organic growth April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition. |
22/04/2010 | Public releases | |
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
19/10/2010 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases |